2022-501822-39-00
Recruiting
Phase 1/2
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression
Philogen S.p.A.12 sites in 3 countries113 target enrollmentStarted: February 15, 2023Last updated:
Overview
- Phase
- Phase 1/2
- Status
- Recruiting
- Sponsor
- Philogen S.p.A.
- Enrollment
- 113
- Locations
- 12
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Teresa Hemmerle
Scientific
Philogen S.p.A.
Study Sites (12)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.2025-522243-17-00Philogen S.p.A.96
Not yet recruiting
Phase 1
A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).2024-515074-26-00AgomAb Therapeutics64
Completed
Phase 1/2
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)2022-502057-33-00Sanofi-Aventis Recherche & Developpement59
Completed
Phase 1
A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess How Long JNJ 77730614 Stays in the Body (Pharmacokinetics) and How the Body Responds to it (Pharmacodynamics)2023-505684-36-00Janssen - Cilag International92
Active, not recruiting
Phase 1
A study to assess the safety and immunogenicity of a therapeutic hepatitis B virus vaccine, in healthy adults (RUBY).2025-521169-28-00AstriVax16